The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS

The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS

Abstract Purpose Rapid development of novel therapeutics in renal cell carcinoma (RCC) has led to financial burden for patients and society. Value including clinical benefit, toxicity affecting quality of life and cost-effectiveness are a concern, prompting the need for tools to facilitate value ass...

Full description

Bibliographic Details
Main Authors: Hyerim Ha, Jin Hyoung Kang, Do Yeun Kim, Seung Jin Bae, Hee Yeon Lee
Format: Article
Language:English
Published: BMC 2022-07-01
Series:BMC Health Services Research
Subjects:
Values
ASCO value framework
ESMO-MCBS
Carcinoma, renal cell
Tyrosine kinase inhibitor
Immune checkpoint inhibitor
Online Access:https://doi.org/10.1186/s12913-022-08279-6

Internet

https://doi.org/10.1186/s12913-022-08279-6

Similar Items